Preoperative treatment with 5α-reductase inhibitors and the risk of hemorrhagic events in patients undergoing transurethral resection of the prostate - A population-based cohort study

Ti-Yuan Yang, Marcelo Chen, Wun-Rong Lin, Chung-Yi Li, Wei-Kung Tsai, Allen W Chiu, Ming-Chung Ko, Ti-Yuan Yang, Marcelo Chen, Wun-Rong Lin, Chung-Yi Li, Wei-Kung Tsai, Allen W Chiu, Ming-Chung Ko

Abstract

Objectives: To assess the associations between preoperative treatment with 5-alpha reductase inhibitors and the risks of blood transfusion during transurethral resection of the prostate and blood clot evacuation or emergency department visits for hematuria within 1 month after surgery.

Methods: We used data from the Taiwan National Health Insurance Research Database in this population-based cohort study. A total of 3,126 patients who underwent first-time transurethral resection of the prostate from 2004 to 2013 were identified. Adjusted odds ratios estimated by multiple logistic regression models were used to assess the independent effects of the preoperative use of 5-alpha reductase inhibitors on the risks of perioperative hemorrhagic events after adjustment for potential confounders.

Results: Two hundred and ninety-seven (9.4%) patients were treated with 5-alpha reductase inhibitors for <3 months, and 65 (2.1%) patients were treated for ≥3 months prior to undergoing transurethral resection of the prostate. The blood transfusion rates for patients who were not treated with 5-alpha reductase inhibitors (controls), patients who were treated with 5-alpha reductase inhibitors for <3 months, and patients who were treated with 5-alpha reductase inhibitors ≥3 months were 9.5%, 8.8%, and 3.1%, respectively. 5-alpha reductase inhibitors tended to decrease the risk of blood transfusion; however, this association was not statistically significant (adjusted odds ratio=0.14, 95% confidence interval: 0.02-1.01). Age ≥80 years, coagulopathy, and a resected prostate tissue weight >50 g were associated with significantly higher risks of blood transfusion than other parameters.

Conclusions: This nationwide study did not show that significant associations exist between 5-alpha reductase inhibitor use before transurethral resection of the prostate and the risks of blood transfusion and blood clot evacuation or emergency visits for hematuria.

Conflict of interest statement

No potential conflict of interest was reported.

References

    1. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64((1)):118–40. doi: 10.1016/j.eururo.2013.03.004.
    1. Kavanagh LE, Jack GS, Lawrentschuk N. Prevention and management of TURP-related hemorrhage. Nat Rev Urol. 2011;8((9)):504–14. doi: 10.1038/nrurol.2011.106.
    1. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50((5)):969–79. doi: 10.1016/j.eururo.2005.12.042.
    1. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180((1)):246–9. doi: 10.1016/j.juro.2008.03.058.
    1. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46((4)):488–94. doi: 10.1016/j.eururo.2004.05.008.
    1. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;55((5)):684–9. doi: 10.1016/S0090-4295(00)00454-4.
    1. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169((1)):20–3. doi: 10.1016/S0022-5347(05)64025-6.
    1. Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology. 2009;73((6)):1274–8. doi: 10.1016/j.urology.2008.08.461.
    1. Tuncel A, Ener K, Han O, Nalcacioglu V, Aydin O, Seckin S, et al. Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. Scand J Urol Nephrol. 2009;43((5)):377–82. doi: 10.3109/00365590903164498.
    1. Lund L, Moller Ernst-Jensen K, Torring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol. 2005;39((2)):160–2. doi: 10.1080/00365590510007694.
    1. Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99((3)):587–94. doi: 10.1111/j.1464-410X.2006.06619.x.
    1. Hsing AW, Ioannidis JP. Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175((9)):1527–9. doi: 10.1001/jamainternmed.2015.3540.
    1. Chen TJ, Chou LF, Hwang SJ. Patterns of ambulatory care utilization in Taiwan. BMC Health Serv Res. 2006;6:54. doi: 10.1186/1472-6963-6-54.
    1. National Health Insurance Research Database. Taiwan. Available at.
    1. Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, et al. Short-term pretreatment with a dual 5&agr;-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int. 2015;116((1)):117–23. doi: 10.1111/bju.12917.
    1. Zhu YP, Dai B, Zhang HL, Shi GH, Ye DW. Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol. 2015;15:47. doi: 10.1186/s12894-015-0043-4.
    1. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology. 2001;58((6)):972–6. doi: 10.1016/S0090-4295(01)01408-X.
    1. Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis. 2005;8((3)):215–8. doi: 10.1038/sj.pcan.4500818.
    1. Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol. 2002;168((5)):2024–6. doi: 10.1016/S0022-5347(05)64287-5.
    1. Pastore AL, Mariani S, Barrese F, Palleschi G, Valentini AM, Pacini L, et al. Transurethral resection of prostate and the role of pharmacological treatment with dutasteride in decreasing surgical blood loss. J Endourol. 2013;27((1)):68–70. doi: 10.1089/end.2012.0231.
    1. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162((20)):2269–76. doi: 10.1001/archinte.162.20.2269.
    1. Mangus RS, Kinsella SB, Nobari MM, Fridell JA, Vianna RM, Ward ES, et al. Predictors of blood product use in orthotopic liver transplantation using the piggyback hepatectomy technique. Transplant Proc. 2007;39((10)):3207–13. doi: 10.1016/j.transproceed.2007.09.029.
    1. Chen JS, Chang CH, Yang WH, Kao YH. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study. BJU Int. 2012;110((11 Pt C)):E896–901.
    1. Tung YC, Chang GM, Chien KL, Tu YK. The relationships among physician and hospital volume, processes, and outcomes of care for acute myocardial infarction. Med Care. 2014;52((6)):519–27. doi: 10.1097/MLR.0000000000000132.
    1. Chen LF, Ho HC, Su YC, Lee MS, Hung SK, Chou P, et al. Association between provider volume and healthcare expenditures of patients with oral cancer in Taiwan: a population-based study. PLoS One. 2013;8((6)):e65077. doi: 10.1371/journal.pone.0065077.
    1. Cote GA, Imler TD, Xu H, Teal E, French DD, Imperiale TF, et al. Lower provider volume is associated with higher failure rates for endoscopic retrograde cholangiopancreatography. Med Care. 2013;51((12)):1040–7. doi: 10.1097/MLR.0b013e3182a502dc.
    1. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57((1)):123–31. doi: 10.1016/j.eururo.2009.09.035.
    1. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349((25)):2387–98. doi: 10.1056/NEJMoa030656.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe